Immunoglobulin E specific for Pinus strobus pollen proteins (sIgE (Pinus strobus))

Immunoglobulin E (IgE) antibodies specific for Pinus strobus (Eastern White Pine) pollen proteins are the primary mediators of Type I hypersensitivity reactions to this specific tree species. Upon initial exposure to Pinus strobus pollen, susceptible individuals undergo sensitization, producing these specific IgE antibodies which then bind to high-affinity FcεRI receptors on the surface of mast cells and basophils (Nature Reviews Immunology, PMID: 26806484). Subsequent exposure to the pollen causes the allergens to cross-link the surface-bound IgE, triggering the immediate release of inflammatory mediators like histamine, leukotrienes, and cytokines. This physiological response results in the clinical manifestations of seasonal allergy, such as sneezing, nasal congestion, and itchy eyes (PubMed, PMID: 11031337). Therapeutic intervention often involves the use of anti-IgE monoclonal antibodies, such as omalizumab, which sequester free circulating IgE and downregulate receptor expression on effector cells (StatPearls, PMID: 29262168). Additionally, allergen-specific immunotherapy (AIT) may be employed to modify the underlying immune response, shifting the antibody profile from IgE toward protective IgG4. Monitoring these specific IgE levels is a standard diagnostic practice for identifying pine pollen allergy and assessing the severity of sensitization.

Other names

Eastern White Pine specific IgEPinus strobus IgEt16 specific IgEAnti-Pinus strobus IgESpecific IgE to Pinus strobus

Anti-IgE monoclonal antibodies bind to the Cε3 domain of circulating IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils, thereby inhibiting the allergic cascade.